FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Belatacept (Nulojix) Lyophilized Powder for Injection
Status: Currently in Shortage
»Date first posted: 03/06/2017
»Therapeutic Categories: Transplant

Bristol Myers Squibb Co. (Revised 02/25/2021)

Company Contact Information:
800-721-5072 ; 877-417-1523

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
20cc vial 250mg lyophilized powder per vial for IV infusion (NDC 0003-0371-13) No disruption to existing patients is anticipated. Until further notice, BMS will continue to limit distribution of Nulojix via the US NULOJIX Distribution Program, initiated 2/15/2017. Starting in August 2018, the restrictions of the NDP were eased to allow for expansion of use to appropriate new patients if the treating physician determines that Nulojix is the best treatment option for the patient. For further information, contact BMS Medical Information. Increased demand for the drug exacerbated by a delay in transition to a more efficient manufacturing process. Demand increase for the drug

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English